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Objective: This study reports the results of a prospective, multicenter trial designed to evaluate the safety and effectiveness
of the Zenith fenestrated endovascular graft (Cook Medical, Bloomington, Ind) for treatment of juxtarenal abdominal
aortic aneurysms (AAAs).
Methods: Sixty-seven patients with juxtarenal AAAs were prospectively enrolled in 14 centers in the United States from
2005 to 2012. Custom-made fenestrated stent grafts were designed with one to three fenestrations on the basis of
analysis of computed tomography data sets. Renal alignment was performed with balloon-expandable stents. Follow-up
included clinical examination, laboratory studies, mesenteric-renal duplex ultrasound, abdominal radiography, and
computed tomography imaging at hospital discharge and at 1 month, 6 months, and 12 months and yearly thereafter
up to 5 years.
Results: There were 54 male and 13 female patients with a mean age of 74 6 8 years enrolled. Mean aneurysm diameter
was 60 6 10 mm. A total of 178 visceral arteries required incorporation with small fenestrations in 118, scallops in 51,
and large fenestrations in nine. Of these, all 118 small fenestrations (100%), eight of the scallops (16%), and one of the
large fenestrations (11%) were aligned by stents. Technical success was 100%. There was one postoperative death within
30 days (1.5%). Mean length of hospital stay was 3.36 2.1 days. No aneurysm ruptures or conversions were noted during
a mean follow-up of 376 17 months (range, 3-65 months). Two patients (3%) had migration$10 mmwith no endoleak,
both due to cranial progression of aortic disease. Of a total of 129 renal arteries targeted by a fenestration, there were four
(3%) renal artery occlusions and 12 (9%) stenoses. Fifteen patients (22%) required secondary interventions for renal artery
stenosis/occlusion in 11 patients, type II endoleak in three patients, and type I endoleak in one patient. At 5 years, patient
survival was 91%6 4%, and freedom from major adverse events was 79%6 6%; primary and secondary patency of targeted
renal arteries was 81% 6 5% and 97% 6 2%, freedom from renal function deterioration was 91% 6 5%, and freedom from
secondary interventions was 63% 6 9%.
Conclusions: This prospective study demonstrates that endovascular repair of juxtarenal AAAs with the Zenith fenestrated
AAA stent graft is safe and effective. Mortality and morbidity are low in properly selected patients treated in centers with
experience in these procedures. (J Vasc Surg 2014;60:1420-8.)the Division of Vascular and Endovascular Surgery, Mayo Clinic,
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Volume 60, Number 6 Oderich et al 1421Endovascular aortic aneurysm repair (EVAR) has
gained widespread acceptance in patients with abdominal
aortic aneurysms (AAAs). Prospective randomized trials
have demonstrated several short-term advantages over
open repair, including less blood loss, operative time, hos-
pital stay, mortality, and morbidity.1-3 The applicability of
these procedures is limited in up to 40% of the patients
by the presence of inadequate neck or involvement of the
visceral arteries. In these patients, open repair remains the
standard treatment in most centers.
Fenestrated endografts have been increasingly used to
treat complex aneurysms involving one or more visceral
branches. These devices are designed with fenestrations
or scallops to incorporate segments of the visceral arteries
into the proximal sealing zone. Intermediate results at
2 years from the ﬁrst 30 patients in the U.S. Zenith Fenes-
trated AAA Endovascular Graft Trial have shown that the
procedure is safe, effective, and associated with high tech-
nical success.4 These results are further corroborated by
single-center reports, multicenter registries, and systematic
reviews indicating that endovascular repair with fenestrated
stent grafts can be performed with high technical success
and lower morbidity and mortality compared with open
conventional repair.5-13 This article reports the results of
all 67 patients enrolled in the trial designed to evaluate
the safety and efﬁcacy of the Zenith fenestrated AAA endo-
vascular graft (Cook Medical, Bloomington, Ind) to treat
juxtarenal AAAs.
METHODS
Details of the study design and methods have been pre-
viously described.4 The study was a prospective, multi-
center, nonrandomized trial conducted in 14 academic
centers in the United States (Supplementary Table I, online
only). Participation in each center required informed con-
sent approved by the Institutional Review Board and
compliance with the study inclusion and exclusion criteria
(Supplementary Table II, online only). Sixty-seven patients
were enrolled in the study, including 42 patients in the
pivotal phase (January 2005 to August 2010) and 25 pa-
tients in the extended access phase (October 2010 to April
2012). This report summarizes results from 67 patients as
of November 2013.
Device design and alignment stents. Aneurysm
morphology was determined by high-resolution computed
tomography angiography (CTA) data sets. Infrarenal aortic
neck was $4 and <15 mm in length. Device design con-
sisted of one to three fenestrations, including small, large,
and scallop fenestrations, with a maximum of two fenes-
trations of the same type (Supplementary Fig 1, online
only). The proposed design was reviewed and approved by
one of two centers with prior experience in device
planningdCleveland Clinic Foundation and William A.
Cook Australia.
Alignment stents were recommended for all vessels
accommodated by small fenestrations, were optional for
scallops, and were not recommended for large fenestra-
tions. The study was initiated allowing use of anycommercially available balloon-expandable stent for align-
ment of fenestrations. After enrollment of the ﬁrst 30
patients, a speciﬁcally designed bare-metal balloon-expand-
able stent (Zenith Alignment stent; Cook Medical, Bloo-
mington, Ind) was available for use. The technical details
of device implantation have been previously described.4-7
Clinical and imaging follow-up. Follow-up consisted
of clinical examination and imaging before discharge and at
1 month, 6 months, and 12 months and annually thereafter
for the ﬁrst 5 years. Imaging evaluation includedCTA or CT
without contrast enhancement, duplex ultrasound of the
visceral arteries, and abdominal radiography. All imaging
studies were independently evaluated at the investigative
sites and core laboratory. Adverse events were reviewed
and adjudicated by an independent clinical event committee.
Statistical analysis. Data were managed and analyzed
by MED Institute Inc with SAS 9.1 software (SAS Insti-
tute, Cary NC). The reporting standards of the Society
for Vascular Surgery for endovascular repair of AAAs
were used to deﬁne technical success, aneurysm sac
changes, endoleak, migration, and device integrity.14
Major adverse events (MAEs) were analyzed by the deﬁ-
nition previously described.4 Renal function deterioration
was deﬁned a priori by serum creatinine rise to >2 mg/dL
and >30% from baseline, detected on two or more follow-
up tests. A more stringent criterion was deﬁned a posteriori
by >30% decrease from baseline in estimated glomerular
ﬁltration rate (eGFR) in two or more follow-up tests.
Other renal events included renal artery stenosis, occlusion,
and kidney parenchymal infarct. For renal arteries targeted
by a fenestration, primary patency was deﬁned a posteriori
as uninterrupted patency from index procedure until oc-
clusion or any renal stent reintervention for stenosis, and
secondary patency was deﬁned a posteriori as an occlusion
treated by surgical bypass or not suitable to endovascular
salvage. Time-dependent outcomes were reported with
Kaplan-Meier estimates. Results were reported as per-
centage for categorical variables and mean 6 standard
deviation for continuous variables. The Fisher exact test
was used for comparing categorical variables. A value of
P < .05 was used to determine statistical signiﬁcance.RESULTS
Study patients. A total of 195 patients underwent
imaging review by the planning center to determine eligi-
bility. Of these, 128 patients (66%) were excluded because
of stringent anatomic criteria listed in Supplementary
Table III (online only). Of the excluded 128 patients,
the most common exclusion criterion was inadequacy of
infrarenal aortic neck (<4 mm or $15 mm in length) in 60
patients (47%).
Sixty-seven patients met all clinical and anatomic
criteria and were included in the study. There were
54 male and 13 female patients with a mean age of
74 6 8 years. Cardiovascular risk factors and anatomic
measurements are summarized in Table I. The mean aneu-
rysm diameter was 60 6 10 mm (range, 47-100 mm). The
Table I. Clinical and anatomic characteristics of patients participating in the Cook Zenith Fenestrated Abdominal Aortic
Aneurysm (AAA) Endovascular Graft Trial
Factors No. or mean 6 SD Percentagea or range
Demographics
Age, years 74.2 6 8.1 52-87
Male 54 81
Body mass index 29.5 6 6.5 18.6-57.6
Cardiovascular risk factors
Hypertension 60 90
Cigarette smoking 59 88
Coronary artery disease 36 54
Arrhythmia 21 31
Myocardial infarction 20 30
Chronic obstructive pulmonary disease 24 36
Chronic kidney disease stage 3b 16 24
Diabetes mellitus 16 24
Peripheral arterial occlusive disease 15 23
Family history of aortic aneurysm disease 12 21
Cerebrovascular disease 11 16
Congestive heart failure 7 10
History of thromboembolic event 7 10
Anatomic characteristics (site assessment)
Maximum aneurysm diameter, long axis, mm 59.7 6 9.7 47-100
Maximum aneurysm diameter, short axis, mm 55.9 6 9.8 37-94
Aortic diameter at the celiac axis, mm 26.5 6 2.6 22-33
Aortic diameter at SMA, mm 25.5 6 2.7 20-32
Aortic diameter at midpoint of renal arteries, mm 24.6 6 2.8 19-31
Aortic diameter at lowest renal artery, mm 24.5 6 3 19-31
Aortic diameter 15 mm distal to lowest renal artery, mm 31.3 6 5.3 20-45
Aortic diameter at the aortic bifurcation, mm 26.2 6 5.8 17-45
Infrarenal neck length, mm 7.5 6 2.3 4-12
Suprarenal to infrarenal axis neck angulation, degree 12.2 6 11.8 0-45
Infrarenal neck to aneurysm axis angulation, degree 20.6 6 14.1 0-45
Diameter of ostia of SMA, mm 8.6 6 1.7 5-14
Diameter of ostia of right renal artery, mm 6.6 6 1 4-8
Diameter of ostia of left renal artery, mm 6.7 6 1 5-10
SD, Standard deviation; SMA, superior mesenteric artery.
aThe denominators for calculation of the percentages did not include patients with missing data or for whom the condition was reported as unknown.
bGlomerular ﬁltration rate # 60 mL/min/1.73 m2.
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Stent graft design. A total of 178 visceral arteries
were incorporated (Table II), including 129 renal arteries
(62 right and 67 left) and 49 superior mesenteric arteries
(SMAs). Fenestrations designed to incorporate these
vessels included 118 small fenestrations for renal arteries,
51 scallops for 40 SMAs and 11 renal arteries, and nine
large fenestrations for SMAs. The most common device
conﬁguration, used in 40 patients (60%), consisted of two
small renal fenestrations and a scallop for the SMA.
Device implantation. Endovascular repair was per-
formed with general endotracheal anesthesia in 52 patients
(78%) or local-regional anesthesia in 15 (22%). The femoral
arteries were surgically exposed in 57 patients (85%) or
accessed percutaneously in nine. One patient (1.5%)
required an iliac conduit. Total anesthesia and procedure
times were 298 6 74 minutes (range, 177-623 minutes)
and 236 6 81 minutes (range, 104-554 minutes), respec-
tively. The mean ﬂuoroscopy time was 60 6 34 minutes
(range, 5-233 minutes), and the mean dose of contrast
material was 42,748 6 24,256 mgI (range, 4500-113,700mgI). The mean time for complete device implantation was
164 6 69 minutes (range, 50-448 minutes). The mean
estimated blood loss was 526 6 490 mL (range, 50-
2400 mL).
Technical success was achieved in all 67 patients, with
all intended target vessels stented (100%). Of 178 visceral
arteries targeted by fenestrations or scallops, alignment
stents were used in 127 (71%) visceral arteries, including
all 118 renal arteries incorporated by small fenestrations,
eight renal arteries incorporated by scallops, and one
SMA targeted by a large fenestration. None of the SMA
scallops were aligned by stents despite the use of single-
width scallop in the design. A total of 135 balloon-
expandable stents were used (Table II), including 115
bare-metal and 20 iCAST covered stents (Atrium, Hudson,
NH). Placement of two stents was required in seven renal
arteries and one SMA because of kink or inadequate over-
lap between the fenestration and the ﬁrst stent. All 178
visceral arteries were patent by completion angiography.
Other adjunctive procedures included iliac angioplasty in
12 patients, iliac stent in six, femoral artery repair or endar-
terectomy in six, and celiac stent in one.
Table II. Device design, fenestration type, and alignment stents in patients participating in the Cook Zenith Fenestrated
Abdominal Aortic Aneurysm (AAA) Endovascular Graft Trial
No. %
Types of fenestrations used for target vessel incorporation
Renal artery 129 72
Small fenestrations 118 66
Scallops 11 6
SMA 49 28
Scallops 40 22
Large fenestration 9 5
Total number of vessels 178 100
Design of proximal fenestrated stent graft
2 small fenestrations and 1 scallop 40 60
2 small fenestrations and 1 large fenestration 9 13
2 small fenestrations 6 9
1 small fenestration and 1 scallop 5 7.5
1 scallop 4 6
1 small fenestration 2 3
1 small fenestration and 2 scallops 1 1.5
Total number of devices 67 100
Alignment stents
Zenith alignment stent (Cook Medical Inc, Bloomington, Ind) 58 43
Express LD stent (Boston Scientiﬁc, Bloomington, Minn) 29 21
eV3 IntraTherapeutics stent (Covidien, Plymouth, Calif) 25 19
iCAST Covered stent (Atrium Maquet, Hudson, NH) 20 15
Palmaz Genesis stent (Cordis, Warren, NJ) 2 1.5
Bridge Assurant stent (Medtronic, Minneapolis, Minn) 1 0.7
Total number of alignment stents 135 100
SMA, Superior mesenteric artery.
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was one early death (1.5%) on postoperative day 2 from
bowel ischemia in a patient treated by two small renal fen-
estrations and a large SMA fenestration, all with alignment
stent placement. The SMA was patent, but the patient had
persistent acidosis, and abdominal distention was observed
at completion of the procedure. Exploratory laparotomy
was performed 2 days after the procedure, when irrevers-
ible ischemia and necrosis involving the jejunum, ileum,
colon, and rectum were found; the patient died about an
hour later.
There were no ruptures or conversions to open repair.
Early complications are shown in Supplementary Table IV
(online only). Eleven patients (16%) had acute blood loss
anemia requiring transfusion. Three patients developed
bowel ischemia, including the patient who died and two
other patients who were treated medically with ﬂuid resus-
citation and antibiotics and had complete resolution. No
patient experienced deterioration of renal function within
the ﬁrst 30 days.
Time to ambulation was 1.3 6 1 days (range,
0-7 days). Regular enteral diet was resumed in 1.4 6
1 days (range, 0-6 days). Mean length of stay was 0.5 6
1.1 days (range, 0-6 days) in the intensive care unit and
3.3 6 2.1 days (range, 1-14 days) in the hospital. Core lab-
oratory review revealed widely patent stent graft and target
visceral arteries in all 58 patients who had predischarge
CTA available for patency assessment and no type I or
type III endoleak in 56 patients with studies available forendoleak assessment. Sixteen patients (29%; 16 of 56)
had a type II endoleak noted on predischarge CTA.
All-cause mortality and MAEs. Of the 66 patients
who survived the ﬁrst 30 days, the mean follow-up was
37 6 17 months (range, 3-65 months). Follow-up was
44 6 17 months (range, 3-65 months) among the 42
patients enrolled in the pivotal study phase, of whom 35
(83%) completed 2 years and 17 (40%) completed 5 years
of follow-up.
There were ﬁve deaths during the study (Table III),
including the aforementioned aneurysm-related death.
Three late deaths were considered by the clinical event com-
mittee to be unrelated to the aneurysm repair and one was
considered to be indeterminate. Freedom from all-cause
mortality was 97% 6 2% at 1 year and 91% 6 4% at 5 years
(Table IV). Twelve patients developed 16 MAEs. These
includeddeath inﬁve patients; congestiveheart failure, bowel
ischemia, or myocardial infarction in three patients each; and
stroke or bowel obstruction in one patient each. Of the 16
MAEs, fourwere considered to be events related to the aneu-
rysm repair by independent adjudication. Freedom from any
MAE was 90% 6 4% at 1 year and 79% 6 6% at 5 years
(Supplementary Fig 2, online only). There were no aneurysm
ruptures or conversions to open repair to date.
Renal events. Eight patients developed asymptomatic
renal infarcts with no clinical consequence, including
seven patients with infarcts diagnosed by predischarge
CTA and one who developed infarct associated with
occlusion of an accessory renal artery stent at 6 months
Table IV. Kaplan-Meier estimates of freedom from stent graft-related events in the Cook Zenith Fenestrated Abdominal
Aortic Aneurysm (AAA) Endovascular Graft Trial
Freedom from adverse event, Kaplan-Meier estimate (standard error)
Aneurysm growtha Endoleaksa Secondary interventions MAEs All-cause mortality
12-month 1.000 (0) 0.668 (0.058) 0.908 (0.036) 0.896 (0.037) 0.970 (0.021)
(n ¼ 63) (n ¼ 41) (n ¼ 57) (n ¼ 58) (n ¼ 63)
(e ¼ 0) (e ¼ 22) (e ¼ 6) (e ¼ 7) (e ¼ 2)
(c ¼ 4) (c ¼ 4) (c ¼ 4) (c ¼ 2) (c ¼ 2)
24-month 1.000 (0) 0.652 (0.059) 0.844 (0.045) 0.862 (0.043) 0.952 (0.027)
(n ¼ 49) (n ¼ 31) (n ¼ 41) (n ¼ 44) (n ¼ 49)
(e ¼ 0) (e ¼ 23) (e ¼ 10) (e ¼ 9) (e ¼ 3)
(c ¼ 18) (c ¼ 13) (c ¼ 16) (c ¼ 14) (c ¼ 15)
36-month 0.935 (0.044) 0.626 (0.062) 0.781 (0.060) 0.791 (0.056) 0.907 (0.041)
(n ¼ 28) (n ¼ 18) (n ¼ 22) (n ¼ 24) (n ¼ 30)
(e ¼ 2) (e ¼ 24) (e ¼ 12) (e ¼ 12) (e ¼ 5)
(c ¼ 37) (c ¼ 25) (c ¼ 33) (c ¼ 31) (c ¼ 32)
48-month 0.935 (0.044) 0.626 (0.062) 0.683 (0.083) 0.791 (0.056) 0.907 (0.041)
(n ¼ 18) (n ¼ 12) (n ¼ 14) (n ¼ 17) (n ¼ 19)
(e ¼ 2) (e ¼ 24) (e ¼ 14) (e ¼ 12) (e ¼ 5)
(c ¼ 47) (c ¼ 31) (c ¼ 39) (c ¼ 38) (c ¼ 43)
60-month 0.880 (0.068) 0.626 (0.062) 0.631 (0.092) 0.791 (0.056) 0.907 (0.041)
(n ¼ 12) (n ¼ 7) (n ¼ 9) (n ¼ 13) (n ¼ 14)
(e ¼ 3) (e ¼ 24) (e ¼ 15) (e ¼ 12) (e ¼ 5)
(c ¼ 52) (c ¼ 36) (c ¼ 43) (c ¼ 42) (c ¼ 48)
c, Cumulative censored; e, cumulative events; MAEs, major adverse events; n, patients at risk.
aBased on imaging analysis by the core laboratory.
Table III. Summary of all-cause mortality and major adverse events (MAEs) in the Cook Zenith Fenestrated Abdominal
Aortic Aneurysm (AAA) Endovascular Graft Trial
MAEsa
Type Days Cause of deaths or event description Clinical event committee adjudication
Deaths
2 Bowel ischemia Procedure related
85 Septic shock, acute MI, and multisystem organ failure Unrelated
677 Unknown Unrelated
754 Atherosclerotic cardiovascular disease and hypertension Unrelated
761 Unknown Unable to determine
Cardiac
76 Anterior septal MI Unrelated
140 Congestive heart failure Unrelated
314 Congestive heart failure Unrelated
625 Congestive heart failure Unrelated
245 Cardiac ischemia requiring intervention Unrelated
854 Cardiac ischemia requiring intervention Unrelated
Gastrointestinal
0 Bowel ischemia Procedure related
8 Bowel ischemia Procedure related
25 Bowel ischemia Procedure related
383 Bowel obstruction Unrelated
Neurologic
992 Stroke Unrelated
MI, Myocardial infarction.
aOne patient may experience more than one MAE.
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renal infarct was 90% 6 4% at 30 days, 88% 6 4% at 1 year,
and 88%6 4% at 5 years. Renal function deterioration by the
predeﬁned criteria occurred in three patients, all after
30 days. Twoof the three patients had chronic kidney disease
stage 3 (GFR # 60 mL/min/1.73 m2) before repair. Ofthese, one patient eventually progressed to dialysis without
renal artery occlusion or stenosis; this was considered unre-
lated to aneurysm repair by independent adjudication.
Freedom from renal function deterioration by the pre-
deﬁned criteriawas 100% at 30 days and 1 year and 91%65%
at 5 years (Table IV; Supplementary Fig 3, online only). By
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eGFR), freedom from renal function deteriorationwas 100%
at 30 days, 92% 6 3% at 1 year, and 83% 6 7% at 5 years.
Of 129 targeted renal arteries, there were four renal
artery occlusions (3%) in four patients and 12 stenoses
(9%) in 10 patients. In addition, one stenosis occurred in
one renal artery, which was not targeted by a fenestration
or stented. No patient had renal stent kink by core labora-
tory review of CT scans and radiographs. Of the 10 patients
with stenosis in targeted renal arteries, nine had reinterven-
tions. Mean time to occlusion or secondary intervention for
stenosis in a target renal artery was 176 16 months (range,
1-51 months). Rate of renal stent occlusion or stenosis was
not signiﬁcantly different for bare-metal stents (13%, 15 of
115) compared with covered stents (5%, 1 of 20; P ¼ .23).
Freedom from renal artery occlusion was 98% 6 1% at
1 year and 97% 6 2% at 5 years (Supplementary Table V,
online only). At 1 and 5 years, primary renal artery patency
was 95% 6 2% and 81% 6 5%, respectively, and secondary
renal artery patency was 98% 6 1% and 97% 6 2%, respec-
tively (Supplementary Fig 4, online only).
Endoleak and aneurysm sac change. One late type I
endoleak (1.5%) was observed for the entire study cohort.
The patient had a proximal type I endoleak at 3 years
treated with coil embolization, which was conﬁrmed by
core laboratory analysis. At last follow-up, aneurysm size
remained stable with no evidence of endoleak. Type II
endoleaks were noted in 16 of 56 patients (29%) at
dismissal, 10 of 49 patients (20%) at 1 year, and six of 32
patients (19%) at 2 years. Most of these were observed with
no intervention. There was no type III or type IV endoleak
(Supplementary Table VI, online only). Freedom from any
endoleak was 67% 6 6% at 1 year and 63% 6 6% at 5 years
(Table IV; Supplementary Table VI, online only).
Three patients with type II endoleaks had aneurysm
enlargement >5 mm. One patient had reintervention for
type II endoleak at 4 years with resolution of endoleak and
no additional growth. A second patient was treated for a
type II endoleak at 9 months but had persistent type II
endoleak at 4 years with aneurysm growth. The third patient
was noted to have an increase in aneurysm size at 3 years,
with no secondary intervention reported. Decrease in aneu-
rysm sac >5 mm was noted in 38 of 54 patients (70%) at
1 year and 29 of 39 patients (74%) at 2 years
(Supplementary Table VII, online only). Freedom from
aneurysmgrowthwas 100% at 1 year and88%67% at 5 years
(Table IV; Supplementary Table VII, online only).
Device migration. Two patients had device migration
$10 mm by core laboratory analysis, which required sec-
ondary intervention in one patient. One patient was iden-
tiﬁed with caudal migration of the fenestrated component
at 24 months, resulting in mild deformation and stenosis
of the right renal stent, which required reintervention
with placement of two renal stents at 883 days. There
was no type I or type III endoleak or deterioration of renal
function, and the patient had 8-mm decrease in aneurysm
sac diameter since implantation of the device. The second
patient had migration identiﬁed at 5 years, with noendoleak, renal stent stenosis, or deterioration of renal
function. In both of these cases, analysis of CTA revealed
cranial progression of aortic disease with further dilation of
the aortic neck in the fenestrated segment, resulting in loss
of ﬁxation and device migration.
Device integrity. Core laboratory analysis of device
integrity issues identiﬁed barb separation in three patients
at 6, 12, and 24 months, respectively; fracture of the prox-
imal Z stent in the inferior apex of a scallop was identiﬁed
in one patient at 12 months. There were two renal stent
fractures affecting an Express LD (Boston Scientiﬁc, Min-
neapolis, Minn) in one (at 12 months) and a Zenith align-
ment stent in the other (at 6 months). None of the patients
with device integrity issues had clinical consequences or
required reintervention.
Secondary interventions. Secondary interventions
were needed in 15 patients (22%). Freedom from secondary
intervention was 91% 6 4% at 1 year, 78% 6 6% at 3 years,
and 63% 6 9% at 5 years (Table IV; Supplementary Fig 5,
online only).
Secondary interventions were performed to treat renal
artery occlusion in two patients and renal stent stenosis in
nine. Two patients with renal artery occlusions underwent
successful renal artery bypass (the other two patients with
renal artery occlusion had stable creatinine levels during
follow-up and did not undergo any reintervention). One
renal artery stenosis failed an endovascular attempt, and
the patient had no other intervention. The remaining eight
patients with 10 in-stent stenoses (all within bare-metal
stents) underwent angioplasty and additional stent place-
ment. Three patients were treated for type II endoleak by
coil embolization in two or laparotomy with ligation of
the inferior mesenteric artery in one. One patient had rest-
enting of renal fenestration with covered stent and later coil
embolization to treat a proximal type I endoleak.
DISCUSSION
This study represents the updated results of the ﬁrst
prospective, multicenter analysis of endovascular repair
with a fenestrated stent graft to treat juxtarenal AAAs.
The Zenith fenestrated stent graft is based on a time-
tested platform, and the data presented in this study extend
our conﬁdence regarding its longer term durability
through 5 years. The observations of high technical success
(100%), low 30-day mortality (1.5%), no conversion or
rupture, only one (1.5%) type I and no type III endoleak,
and high secondary target renal stent patency (97%) sup-
port the safety, effectiveness, and durability of the Zenith
fenestrated stent graft and serve as a benchmark for com-
parison with other devices or alternative endovascular tech-
niques to treat similar anatomy.
Prospective randomized studies have shown that
EVAR has several short-term advantages over open repair,
including lower mortality.1-3 The perioperative survival
advantage of endovascular repair is sustained for several
years, after which it is lost. Although Level I evidence is
not yet available for repair with use of fenestrated stent
grafts, it seems logical that an endovascular approach will
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greater risk in patients with juxtarenal AAAs who need
more extensive reconstruction. Systematic reviews have
shown that endovascular repair with fenestrated stent grafts
can signiﬁcantly reduce mortality, morbidity, and renal
dysfunction compared with open repair.12,13 Tsilimparis
et al reported that open repair was associated with a ﬁvefold
increase in mortality (5% vs 1%) and twofold increase in
complications (40% vs 20%), including a 10-fold increase
in renal and pulmonary complications.13
The argument supporting open repair relates to its long-
term durability in contrast to the higher reintervention rates
noted for endovascular approaches. Unfortunately, open
surgical reports are retrospective, and few if any have criti-
cally analyzed late outcomes such as branch patency, renal
function changes, aneurysm degeneration, and secondary
aortic or laparotomy-related complications. Endovascular
repair has been associated with more reinterventions than
surgical repair in the Dutch Randomized Endovascular
Aneurysm Management (DREAM) and EVAR trials.1,2
However, these two studies did not include laparotomy-
related complications. In the Open vs Endovascular Repair
(OVER) trial, which included laparotomy-related problems,
there was no difference in reintervention rates, which aver-
aged 20% for both groups.3 Oderich et al reported late out-
comes of open juxtarenal aneurysm repair with use of an
endovascular classiﬁcation based on the estimated number
of fenestrations, had the patient been treated by endovascu-
lar approach.15 For patients requiring up to two small fenes-
trations, implying equipoise to the Zenith fenestrated
cohort, freedom from any reintervention was 78% at 3 years,
which is identical to the Zenith fenestrated study and similar
to the Zenith AAA pivotal study (83%).16
The importance of device planning and sizing cannot
be overemphasized. In this study, all patients were
reviewed by experienced implanters and at the Cook
Australia planning center. The proximal landing zone was
selected within normal aorta, which was recommended
by experienced operators to be >2 cm of parallel aortic
wall with at least 4 mm of infrarenal neck and no thrombus,
calcium, or angulation. The device was customized to
maximize the proximal landing zone within the constraints
of the design, which included up to three fenestrations.
Successful aneurysm exclusion achieved by a fenestrated
stent graft positioned within a normal aortic segment is
supported by the rare occurrence of type I or type III
endoleak and sac shrinkage achieved in more than 70% of
our patients. The stringent anatomic criteria in the study
may account for differences in endoleak rate compared
with other series of fenestrated endografts and alternative
techniques such as snorkel or chimney grafts.10,17,18
Despite the rigorous selection process in this study,
two patients had migration of the fenestrated component
due to cranial progression of aortic disease. England et al
reported a much higher migration rate of 22%.19 It is difﬁ-
cult to determine if the selection process used for device
planning in that study was as rigorous as the one used in
the Zenith fenestrated trial, but clearly progression of aorticdisease should be taken into consideration. The Cleveland
Clinic group noted migration >5 mm in only seven of 650
patients (1%) included in a prospective study using selec-
tion of >2 cm of proximal landing zone within normal
aortic segments.20
The need to routinely align fenestrations with stents has
been well established since the early reports from Western
Australia, which identiﬁed more vessel occlusions when
stents were not used to align fenestrations.5 Since then,
target vessel patency has been reported to be >95% at 3 to
5 years.9,10,20 The clinician’s choice of type of stent has
evolved from bare-metal stents to covered stents on the basis
of recent reports of higher patency rates for covered stents
(95%) compared with bare-metal stents (89%).21 In that
study, bare-metal stents were more prone to in-stent steno-
sis in the proximal stent segment, probably because of
neointimal hyperplasia from intimal and medial injury
triggered by “ﬂaring” of the proximal stent. Conversely,
covered stents may have impeded ingrowth of tissue either
by acting as a barrier or rendering the arterial wall ischemic.
Another advantage of covered stents is protection from type
III endoleak if the vessel originates from abnormal aorta.
Preservation of renal function is critical, given that renal
insufﬁciency is an important predictor of mortality after
aortic surgery.1-3 Patients undergoing fenestrated repair
are subjected to risk of renal function deterioration from
numerous causes.5-13 Similar to other complex endovascular
procedures, common causes of renal dysfunction include
progression of parenchymal disease, embolization of ather-
omatous debris during catheter manipulations, and toxicity
from repeated doses of iodinated contrast material, which
are needed for device implantation and during surveillance
studies. In some patients, renal function is lost from lesions
created by the procedure or from device-related complica-
tions. Late occlusion of renal stents is infrequent and has
been related to dissection, small vessel diameter (<4 mm),
or renal occlusive disease.21 In this trial, freedom from renal
function deterioration (91%) and freedom from renal stent
occlusion (97%) were high at 5 years.
A few technical lessons should be emphasized from the
experience accumulated in this trial and worldwide. Renal
artery motion is higher distal to the middle third of the
renal artery, indicating that stents should be kept as short
in length (<2 cm) as possible.22 The posterior orientation
of a renal artery, especially on the right, may predispose to
kinks distal to the stent edge, which can be difﬁcult to
detect on completion angiography and more commonly
anticipated on the basis of preoperative imaging. In these
cases, a short ﬂexible self-expandable stent extension may
be added as a bridge between the rigid balloon-
expandable stent and the native artery, aiding in compli-
ance mismatch. Debate continues about the need to place
alignment stents in SMA or renal scallops. Although there
were no instances of occlusion in the Zenith fenestrated
trial, others have noted shuttering of the SMA by the fabric
of single-width scallops, which may lead to bowel ischemic
complications.8-10 In addition, placement of the distal
bifurcated component can result in damage to alignment
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inﬂation of an angioplasty balloon during advancement and
retrieval of the distal device cannula.
Finally, a variety of creative approaches have been used
to extend the indications of EVAR to patients with unfa-
vorable anatomy.17,18,23 The concept of parallel stent grafts
(eg, chimney, snorkel, periscope, or sandwich grafts) to
maintain visceral branch patency and to extend the seal
zone has been popularized, but concern remains about
the effects of “gutter” endoleak on long-term durability
as well as branched vessel patency.17,18 Although technical
success is high, two systematic reviews have shown that
operative mortality (6% and 4.3%) and rate of type I endo-
leak (10% and 14%) are unquestionably higher than the re-
sults herein described in this trial.17,18 Another approach
that has gained popularity is the use of physician-
modiﬁed fenestrated stent grafts, but limitations include
lack of quality control, inconsistent use of modiﬁcations,
potential risk of device contamination, and integrity issues
that could originate from structural changes in the device.23
The primary limitations of this study relate to the non-
randomized design and lack of surgical control group,
which preclude any deﬁnitive comparison with open surgi-
cal repair or alternative endovascular techniques beyond a
discussion of historical results. Despite the study’s mean
follow-up of >3 years, many patients have not reached
their 5-year end point, thereby restricting the power of
our statistical analysis. The stringent anatomic require-
ments used in this study should be taken into consideration
in comparing results with alternative techniques, such as
parallel grafts or open repair. Finally, the predominant
use of a bare-metal stent for renal alignment differs from
current practice standards and may have accounted for
higher rates of renal stenosis in this trial.
CONCLUSIONS
This study presents the results of the Zenith fenestrated
trial. Overall, results have shown that endovascular repair of
juxtarenal AAAs with a Zenith fenestrated stent graft is
safe, effective, and durable. The high technical success,
low mortality, rare occurrence of type I or type III endo-
leak, high target vessel patency, and lack of conversion to
open repair or aneurysm rupture relate to the integrity of
the device, the proper selection of patients, and the tech-
nical abilities of our investigators. These results are similar
to what has been achieved with the parent Zenith stent
graft for infrarenal aneurysms and to other single-center ex-
periences with fenestrated stent grafts. Still, a rigorous
follow-up is recommended in these patients. Continued
emphasis should be placed on training, reﬁnement of de-
vice design and alignment stents, and evolution of implan-
tation techniques.
The U.S. Zenith fenestrated study represents the ideas
and concepts of our mentor, friend, and leader, Dr Roy K.
Greenberg, who served as national principal investigator
from the inception of the trial to its completion of enroll-
ment in 2012.The authors thank Qing Zhou, PhD, for assistance in
data analysis and preparing data summaries, and Mr David
Factor for preparation of illustrations for this manuscript.
AUTHOR CONTRIBUTIONS
Conception and design: RG, PB
Analysis and interpretation: GO, RG, MF, SL, LS, RF, FJ,
PB
Data collection: GO, RG, MF, SL, LS, RF, FJ, PB
Writing the article: GO, MF, SL, LS, RF, FJ, PB
Critical revision of the article: GO, MF, SL, LS, RF, FJ, PB
Final approval of the article: GO, MF, SL, LS, RF, FJ, PB
Statistical analysis: GO, RG, MF, SL, LS, RF, FJ, PB
Obtained funding: Industry-sponsored study
Overall responsibility: GOREFERENCES
1. Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D,
Sculpher MJ. Endovascular versus open repair of abdominal aortic
aneurysm. N Engl J Med 2010;362:1863-71.
2. De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven EL,
Cuypers PW, et al. Long-term outcome of open or endovascular repair
of abdominal aortic aneurysm. N Engl J Med 2010;362:1881-9.
3. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr,
Matsumura JS, Kohler TR, et al. Open vs Endovascular Repair
(OVER) Veterans Affairs Cooperative Study Group. Outcomes
following endovascular vs open repair of abdominal aortic aneurysm: a
randomized trial. JAMA 2009;302:1535-42.
4. Greenberg RK, Sternbergh WC 3rd, Makaroun M, Ohki T, Chuter T,
Bharadwaj P, et al. Intermediate results of a United States multicenter
trial of fenestrated endograft repair for juxtarenal abdominal aortic
aneurysms. J Vasc Surg 2009;50:730-7.
5. Semmens JB, Lawrence-Brown MM, Hartley DE, Allen YB, Green R,
Nadkarni S. Outcomes of fenestrated endografts in the treatment of
abdominal aortic aneurysm in Western Australia (1997-2004).
J Endovasc Ther 2006;13:320-9.
6. Greenberg RK, West K, Pfaff K, Foster J, Skender D, Haulon S, et al.
Beyond the aortic bifurcation: branched endovascular grafts for thor-
acoabdominal and aortoiliac aneurysms. J Vasc Surg 2006;43:879-86.
7. O’Neill S, Greenberg RK, Haddad F, Resch T, Sereika J, Katz E.
A prospective analysis of fenestrated endovascular grafting: intermediate-
term outcomes. Eur J Vasc Endovasc Surg 2006;32:115-23.
8. Amiot S, Haulon S, Becquemin JP, Magnan PE, Lermusiaux P,
Gouefﬁc Y, et al. Fenestrated endovascular grafting: The French
multicenter experience. Eur J Vasc Endovasc Surg 2010;39:537-44.
9. Verhoeven EL, Vourliotakis G, Bos WT, Tielliu IF, Zeebregts CJ,
Prins TR, et al. Fenestrated stent grafting for short-necked and jux-
tarenal abdominal aortic aneurysm: an 8-year single-centre experience.
Eur J Vasc Endovasc Surg 2010;39:529-36.
10. Kristmundsson T, Sonesson B, Dias N, Törnqvist P, Malina M,
Resch T. Outcomes of fenestrated endovascular repair of juxtarenal
aortic aneurysm. J Vasc Surg 2014;59:115-20.
11. British Society for Endovascular Therapy and the GLOBALSTAR Reg-
istry. Early results of fenestrated endovascular repair of juxtarenal aortic
aneurysms in the United Kingdom. Circulation 2012;125:2707-15.
12. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM.
Modern treatment of juxtarenal abdominal aortic aneurysms with
fenestrated endografting and open repairda systematic review. Eur J
Vasc Endovasc Surg 2009;38:35-41.
13. Tsilimparis N, Perez S, Dayama A, Ricotta JJ 2nd. Endovascular repair
with fenestrated-branched stent grafts improves 30-day outcomes for
complex aortic aneurysms compared with open repair. Ann Vasc Surg
2013;27:267-73.
14. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Ad Hoc Committee for Standardized Reporting
JOURNAL OF VASCULAR SURGERY
1428 Oderich et al December 2014Practices in Vascular Surgery of The SVS/AAVS. Reporting standards
for endovascular aortic aneurysm repair. J Vasc Surg 2002;35:1048-60.
15. Oderich GS, Tallarita T, Kalra M, Duncan A, Gloviczki P, Vrtiska T,
et al. Contemporary results of open complex abdominal aortic aneu-
rysm repair using a standardized classiﬁcation for comparison with
fenestrated endografts. J Vasc Surg 2011;53:27S-8S.
16. Greenberg RK, Chuter TA, Cambria RP, Sternbergh WC 3rd,
Fearnot NE. Zenith abdominal aortic aneurysm endovascular graft.
J Vasc Surg 2008;48:1-9.
17. Moulakakis KG, Mylonas SN, Avgerinos E, Papapetrou A, Kakisis JD,
Brountzos EN, et al. The chimney graft technique for preserving
visceral vessels during endovascular treatment of aortic pathologies.
J Vasc Surg 2012;55:1497-503.
18. Wilson A, Zhou S, Bachoo P, Tambyraja AL. Systematic review of
chimney and periscope grafts for endovascular aneurysm repair. Br J
Surg 2013;100:1557-64.
19. England A, García-Fiñana M, Fisher RK, Naik JB, Vallabhaneni SR,
Brennan JA, et al. Migration of fenestrated aortic stent grafts. J Vasc
Surg 2013;57:1543-52.20. Mastracci TM, Greenberg RK, Eagleton MJ, Hernandez AV. Dura-
bility of branches in branched and fenestrated endografts. J Vasc Surg
2013;57:926-33.
21. Mohabbat W, Greenberg RK, Mastracci TM, Cury M, Morales JP,
Hernandez AV. Revised duplex criteria and outcomes for renal stents
and stent grafts following endovascular repair of juxtarenal and thor-
acoabdominal aneurysms. J Vasc Surg 2009;49:827-37.
22. Draney MT, Zarins CK, Taylor CA. Three-dimensional analysis of
renal artery bending motion during respiration. J Endovasc Ther
2005;12:380-6.
23. Starnes BW. Physician-modiﬁed endovascular grafts for the treatment
of elective, symptomatic, or ruptured juxtarenal aortic aneurysms.
J Vasc Surg 2012;56:601-7.Submitted Apr 16, 2014; accepted Aug 6, 2014.
Additional material for this article may be found online
at www.jvascsurg.org.
Supplementary Table I (online only). Participating centers in the Cook Zenith Fenestrated Abdominal Aortic
Aneurysm (AAA) Endovascular Graft Trial
Institution Location Site principal investigator Patients enrolled, No.
Cleveland Clinic Foundation Cleveland, Ohio Sean Lyden, MD 10
Massachusetts General Hospital Boston, Mass Christopher Kwolek, MD 8
University of Pittsburgh Medical Center Pittsburgh, Pa Michel Makaroun, MD 8
University of North Carolina Chapel Hill, NC Mark Farber, MD 8
University of California San Francisco/VA San Francisco, Calif Linda Reilly, MD 7
Barnes-Jewish Hospital St. Louis, Mo Gregorio Sicard, MD 7
Hospital of the University of Pennsylvania Philadelphia, Pa Ronald Fairman, MD 6
Mayo Clinic Rochester, Minn Gustavo Oderich, MD 5
New York University New York, NY Neal Cayne, MD 2
Dartmouth Hitchcock Medical Center Lebanon, NH Mark Fillinger, MD 2
Harborview Medical Hospital Seattle, Wash Benjamin Starnes, MD 1
Shands Hospital Gainesville, Fla Adam Beck, MD 1
The Indiana Heart Hospital Indianapolis, Ind Ali Shahriari, MD 1
University of Massachusetts Worcester, Mass Andres Schanzer, MD 1
Total 67
Supplementary Table II (online only). Inclusion and exclusion criteria for the Cook Zenith Fenestrated Abdominal
Aortic Aneurysm (AAA) Endovascular Graft Trial
Inclusion criteria
d Aortic or aortoiliac aneurysm with diameter $5 cm
d Aortic or aortoiliac aneurysm with a history of growth $0.5 cm per year, or clinical indication for AAA repair
Exclusion criteria
General exclusion criteria
d Younger than 18 years
d Life expectancy less than 2 years
d Pregnant or breast-feeding
d Unwilling to comply with the follow-up schedule
d Inability or refusal to give informed consent
Medical exclusion criteria
d Baseline creatinine >2.0 mg/dL
d Cultural objection to receipt of blood or blood products
d Allergy to stainless steel, polyester, solder, gold, or nitinol
d Anaphylactic reaction to contrast material that cannot be adequately premedicated
d Leaking/ruptured or symptomatic aneurysm
d Uncorrectable coagulopathy
d Previous stent in any renal or visceral artery to be accommodated with a small fenestration
Anatomic exclusion criteria
d Signiﬁcant occlusive disease, tortuosity, or calciﬁcation
d Proximal neck <4 mm or $15 mm in length unless otherwise compromised to preclude seal
d Proximal neck, measured outer wall to outer wall on a sectional image (CT), >31 mm in diameter or <19 mm in diameter
d Proximal neck angulated more than 45 degrees relative to the long axis of the aneurysm
d Immediate suprarenal neck angulated more than 45 degrees relative to the immediate infrarenal neck
d Proximal neck diameter change over the length of the proximal seal zone $4 mm
d Proximal seal site with circumferential thrombus/atheroma above the renal arteries
d Iliac artery diameter, measured inner wall to inner wall on a sectional image (CT), <7.5 mm at any point along access length
(before deployment)
d Ipsilateral iliac artery ﬁxation site diameter, measured inner wall to inner wall on a sectional image (CT), <9.0 mm
(before deployment)
d Iliac artery diameter, measured outer wall to outer wall on a sectional image (CT), >21 mm at distal ﬁxation site
d Iliac artery distal ﬁxation site <30 mm in length
d Inability to maintain at least one patent hypogastric artery
d Renal artery stenosis >50%
d Nonbifurcated segment of any artery to be stented <15 mm in length
d Artery to be stented with a maximum diameter <3 mm or >8 mm at the vessel ostium
d Unsuitable arterial anatomy
CT, Computed tomography.
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Supplementary Fig 1 (online only). A, Preoperative computed tomography angiography (CTA) of a patient with
juxtarenal abdominal aortic aneurysm (AAA) treated by Zenith fenestrated stent graft (B). C, Follow-up CTA with
patent stent graft and no endoleak. Reproduced with permission of Mayo Foundation for Medical Education and
Research. All rights reserved.
Supplementary Table III (online only). Reasons for anatomic exclusion from participation in the Cook Zenith
Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Trial
Criteriaa No.
Proximal neck <4 mm or >15 mm in length 60
Proximal neck diameter change over the length of the proximal seal zone >4 mm 37
Proximal neck >31 mm or <19 mm in diameter 34
Unsuitable arterial anatomy 33
Iliac artery diameter <0.5 mm at any point along access length 32
Proximal neck angulation >45 degrees relative to the long axis of the aneurysm 14
Signiﬁcant occlusive disease, tortuosity, or calciﬁcation 12
Suprarenal neck angulation >45 degrees relative to the immediate infrarenal neck 9
Nonbifurcated segment of any artery to be stented <15 mm in length 9
Renal artery stenosis >50% 8
Ipsilateral iliac artery ﬁxation site diameter <9.0 mm 7
Proximal seal site with circumferential thrombus/atheroma above the renal arteries 6
Inability to maintain at least one patent hypogastric artery 6
Iliac artery distal ﬁxation site <30 mm in length 5
Aortic or aortoiliac aneurysm with diameter of #5 cm 4
Iliac artery diameter >21 mm at distal ﬁxation site 4
Artery to be stented with a maximum diameter <3 mm or >8 mm at the vessel ostium 2
Total number of patients excluded 128
aA patient may meet more than one exclusion criterion.
JOURNAL OF VASCULAR SURGERY
1428.e2 Oderich et al December 2014
Supplementary Table IV (online only). Early and late complications in patients participating in the Cook Zenith
Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Trial
Complications
Early (#30 days) (n ¼ 67) Late (>30 days) (n ¼ 66)
No. % No. %
Cardiac
Arrhythmia requiring intervention or new treatment 2 3 4 6.1
Cardiac ischemia requiring intervention 0 0 2 3
Congestive heart failure 0 0 3 4.5
Q-wave myocardial infarction 0 0 1 1.5
Non-Q-wave myocardial infarction 0 0 1 1.5
Gastrointestinal
Bowel/mesenteric ischemia 3 4.5 0 0
Bowel obstruction 0 0 1 1.5
Paralytic ileus > 4 days 1 1.5 0 0
Neurologic
Stroke 0 0 1 1.5
TIA/RIND 0 0 0 0
Spinal cord ischemia/paralysis 0 0 0 0
Pulmonary
Supplemental oxygen at discharge 2 3 1 1.5
Ventilation > 24 hours 1 1.5 0 0
Pneumonia requiring antibiotics 0 0 8 12
Renal
Renal infarct 7 10 1 1.5
Renal artery stenosis 1 1.5 9 14
Renal artery occlusion 0 0 4 6.1
Serum creatinine rise to > 2 mg/dL and > 30%a 0 0 3 4.5
Vascular
Embolization resulting in tissue loss or intervention 2 3 0 0
Limb thrombosis 0 0 0 0
Pseudoaneurysm 0 0 0 0
Vascular injury 1 1.5 0 0
Wound
Incisional hernia 0 0 2 3
Seroma requiring treatment 0 0 1 1.5
Wound complication requiring return to operation room 1 1.5 0 0
Wound infection 2 3 2 3
RIND, Reversible ischemic neurologic deﬁcit; TIA, transient ischemic attack.
aMeasured in two or more tests.
Supplementary Fig 2 (online only). Kaplan-Meier survival esti-
mates of freedom from major adverse event (MAE) in the U.S.
Zenith Fenestrated Abdominal Aortic Aneurysm (AAA) Endo-
vascular Stent Graft Trial.
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Supplementary Table V (online only). Kaplan-Meier estimates of freedom from renal adverse events in the Cook
Zenith Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Trial
Examination period
Freedom from adverse event, Kaplan-Meier estimate (standard error)
Renal infarcta Renal function deteriorationb Dialysisc Renal artery occlusion
1-month 0.895 (0.037) 1.000 (0) 1.000 (0) 1.000 (0)
(n ¼ 59) (n ¼ 66) (n ¼ 66) (n ¼ 66)
(e ¼ 7) (e ¼ 0) (e ¼ 0) (e ¼ 0)
(c ¼ 0) (c ¼ 0) (c ¼ 0) (c ¼ 0)
12-month 0.880 (0.040) 1.000 (0) 1.000 (0) 0.969 (0.022)
(n ¼ 56) (n ¼ 62) (n ¼ 62) (n ¼ 61)
(e ¼ 8) (e ¼ 0) (e ¼ 0) (e ¼ 2)
(c ¼ 2) (c ¼ 4) (c ¼ 4) (c ¼ 3)
24-month 0.880 (0.040) 0.981 (0.019) 1.000 (0) 0.937 (0.031)
(n ¼ 43) (n ¼ 47) (n ¼ 48) (n ¼ 45)
(e ¼ 8) (e ¼ 1) (e ¼ 0) (e ¼ 4)
(c ¼ 15) (c ¼ 18) (c ¼ 18) (c ¼ 17)
36-month 0.880 (0.040) 0.947 (0.038) 1.000 (0) 0.937 (0.031)
(n ¼ 28) (n ¼ 28) (n ¼ 30) (n ¼ 27)
(e ¼ 8) (e ¼ 2) (e ¼ 0) (e ¼ 4)
(c ¼ 30) (c ¼ 36) (c ¼ 36) (c ¼ 35)
48-month 0.880 (0.040) 0.912 (0.050) 1.000 (0) 0.937 (0.031)
(n ¼ 18) (n ¼ 16) (n ¼ 19) (n ¼ 18)
(e ¼ 8) (e ¼ 3) (e ¼ 0) (e ¼ 4)
(c ¼ 40) (c ¼ 47) (c ¼ 47) (c ¼ 44)
60-month 0.880 (0.040) 0.912 (0.050) 1.000 (0) 0.937 (0.031)
(n ¼ 14) (n ¼ 11) (n ¼ 14) (n ¼ 14)
(e ¼ 8) (e ¼ 3) (e ¼ 0) (e ¼ 4)
(c ¼ 44) (c ¼ 52) (c ¼ 52) (c ¼ 48)
c, Cumulative censored; e, cumulative events; n, patients at risk.
aAs reported by sites, regardless of whether conﬁrmed by core laboratory.
bIncrease in serum creatinine >2 mg/dL and >30% from baseline in two or more tests.
cDialysis in patients with normal preoperative renal function.
Supplementary Fig 3 (online only). Kaplan-Meier survival esti-
mates of freedom from renal function deterioration in the U.S.
Zenith Fenestrated Abdominal Aortic Aneurysm (AAA) Endo-
vascular Stent Graft Trial.
Supplementary Fig 4 (online only). Kaplan-Meier survival esti-
mates of primary and secondary target renal stent patency in the
U.S. Zenith Fenestrated Abdominal Aortic Aneurysm (AAA)
Endovascular Stent Graft Trial.
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Supplementary Table VII (online only). Aneurysm sac changes in the Cook Zenith Fenestrated Abdominal Aortic
Aneurysm (AAA) Endovascular Graft Trial
Change in aneurysm size
Time point, % (n/N)
30 Days 6 Months 12 Months 24 Months 3 Years 4 Years 5 Years
Increase (>5 mm) 0 (0/59) 0 (0/58) 0 (0/54) 0 (0/39) 11 (2/19) 6.3 (1/16) 0 (0/12)
No change 98 (58/59) 48 (28/58) 30 (16/54) 26 (10/39) 16 (3/19) 19 (3/16) 25 (3/12)
Decrease (>5 mm) 1.7 (1/59) 52 (30/58) 70 (38/54) 74 (29/39) 74 (14/19) 75 (12/16) 75 (9/12)
Supplementary Table VI (online only). Endoleak classiﬁcation and incidence in the Cook Zenith Fenestrated
Abdominal Aortic Aneurysm (AAA) Endovascular Graft Trial
Type of endoleak
Time point,a % (n/N)
Predischarge 30 Days 6 Months 12 Months 24 Months 3 Years 4 Years 5 Years
New endoleak 30 (17/56) 5.0 (3/60) 3.8 (2/53) 4.1 (2/49) 3 (1/32) 0 (0/17) 0 (0/12) 0 (0/9)
Any endoleak 30 (17/56) 23 (14/60) 21 (11/53) 27 (13/49) 19 (6/32) 18 (3/17) 17 (2/12) 0 (0/9)
Type I 0 (0/56) 0 (0/60) 0 (0/53) 0 (0/49) 0 (0/32) 0 (0/17) 0 (0/12) 0 (0/9)
Type II 29 (16/56) 23 (14/60) 20 (10/53) 20 (10/49) 19 (6/32) 18 (3/17) 17 (2/12) 0 (0/9)
Type III 0 (0/56) 0 (0/60) 0 (0/53) 0 (0/49) 0 (0/32) 0 (0/17) 0 (0/12) 0 (0/9)
Type IV 0 (0/56) 0 (0/60) 0 (0/53) 0 (0/49) 0 (0/32) 0 (0/17) 0 (0/12) 0 (0/9)
Unknown 1.8 (1/56) 0.0 (0/60) 1.9 (1/53) 6 (3/49) 0 (0/32) 0 (0/17) 0 (0/12) 0 (0/9)
aIn some patients, the same endoleak was detected at multiple time points.
Supplementary Fig 5 (online only). Kaplan-Meier survival esti-
mates of freedom from secondary intervention in the U.S. Zenith
Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular
Stent Graft Trial.
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